Author:
Gasbarrini Nadia,Dubravić Davor,Combs Lauren,Dišković Arian,Ankiersztejn-Bartczak Magdalena,Colaiaco Francesca,Wawer Iwona,Wysocki Piotr,Rosińska Magdalena,Marzec-Boguslawska Anna,Collins Ben,Simões Daniel,Jakobsen Marie Louise,Raben Dorthe
Abstract
Abstract
Background
Maximising access to testing by targeting more than one infection is effective in identifying new infections in settings or populations. Within the EU funded Joint Action INTEGRATE, this paper examined the feasibility and impact of expanding integrated testing for HIV, hepatitis C (HCV), chlamydia, gonorrhoea and/or syphilis in four community-based pilots through targeted interventions in Croatia, Italy and Poland and the Spring European Testing Week since community settings are key in detecting new infections and reaching key populations.
Methods
Pilots led by local INTEGRATE partners prioritised testing for other infections or key populations. The Croatian pilot expanded testing for men who have sex with men to syphilis, chlamydia and gonorrhoea. Italian partners implemented a HIV and HCV testing/information event at a migrant centre. A second Italian pilot tested migrants for HIV and HCV through outreach and a low-threshold service for people who use drugs. Polish partners tested for HIV, HCV and syphilis among people who inject drugs in unstable housing via a mobile van. Pilots monitored the number of individuals tested for each infection and reactive results.
The pilot Spring European Testing Week from 18 to 25 May 2018 was an INTEGRATE-driven initiative to create more testing awareness and opportunities throughout Europe.
Results
The Croatian pilot found a high prevalence for each syphilis, chlamydia and gonorrhoea respectively, 2.1%, 12.4% and 6.7%. The Italian migrant centre pilot found low proportions who were previously tested for HIV (24%) or HCV (11%) and the second Italian pilot found an HCV prevalence of 6.2%, with low proportions previously tested for HIV (33%) or HCV (31%). The Polish pilot found rates of being previously tested for HIV, HCV and syphilis at 39%, 37%, and 38%, respectively. Results from the Spring European Testing Week pilot showed it was acceptable with increased integrated testing, from 50% in 2018 to 71% in 2019 in participants.
Conclusions
Results show that integrated testing is feasible and effective in community settings, in reaching key populations and minimising missed testing opportunities, and the pilots made feasible because of the European collaboration and funding. For sustainability and expansion of integrated community testing across Europe, local government investment in legislation, financial and structural support are crucial.
Funder
Third Health Programme of the European Union
Gilead Sciences
ViiV Healthcare
Janssen Pharmaceuticals
Merck
City of Zagreb - Croatia, cooperation programmes
Ministry of Health, Croatia, cooperation programmes
Cepheid
Department of Immunological and Molecular Diagnostics of the Clinic for Infectious Diseases Dr Fran Mihaljević
Health Department of Lazio Regional Administration of Italy
Fundação para a Ciência e Tecnologia
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Dara M, Ehsani S, Mozalevskis A, Vovc E, Simões D, Avellon Calvo A, et al. Tuberculosis, HIV, and viral hepatitis diagnostics in eastern Europe and central Asia: high time for integrated and people-centred services. Lancet Infect Dis. 2020;20(2):e47–53.
2. European Parliament. European Parliament resolution of 5 July 2017 on the EU’s response to HIV/AIDS, Tuberculosis and Hepatitis C (2017/2576(RSP)). Strasbourg: European Union: European Parliament; 2017.
3. European Centre for Disease Prevention and Control. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA: An integrated approach. Stockholm: ECDC; 2018.
4. World Health Organization. Consolidated guidelines on HIV testing services. Geneva: WHO; 2015.
5. INTEGRATE Joint Action. INTEGRATE Joint Action: INTEGRATE Joint Action; 2020. https://integrateja.eu/.